biorasi Blogs

  1. Best Care Scenario: Nephrology Patient Safety Starts In The Clinical Trial Setting 10/12/2022

    Is the clinical trial setting the best environment to ensure a patient’s safety? Dr. Jamie P. Dwyer discusses how nephrology clinical trials identify future patient risk factors for medication and treatment in the real-world setting.

  2. Where Are The Patients? How Optimized Marketing Accelerates Clinical Trial Enrollment 7/14/2022

    What if you held a clinical trial and no one showed up? With clinical trial delays reaching up to $8M per day, discover why trial stakeholders need to be acutely aware of their study in order to make it a success.

  3. What Went Wrong: Three Major Challenges To Alzheimer's Disease Drug Discovery 6/20/2022

    Why doesn’t a cure exist yet for Alzheimer's disease? There is no simple answer to this question. However, a deeper understanding of the disease process and a closer look at clinical trial challenges may help to shed some light.

  4. Beyond Happy Accidents: Embracing The Complexity Of Precision Medicine 3/31/2022

    Dr. Robert Negrin explains the need to embrace both serendipity and complexity in order to better understand precision medicine.

  5. Elevated Risk: Exploring The Links Between Chronic Kidney Disease And Cardiovascular Disease 2/4/2022

    Chronic kidney disease has become inextricably linked with cardiovascular conditions, a discovery that has yielded synergistic diagnosis and intervention methods. Dr. Jamie Dwyer explores the connection between these two diseases, which has brought about a sort of renaissance for nephrology research.

  6. No Shortcuts: Two Pathways To Building A Future For Huntington's Disease Research 11/16/2021

    One of the tenets of clinical research is that findings often result in more questions than answers. For Huntington’s disease, the journey toward understanding and treatment continues to be a methodical one. Dr. Ole Isacson highlights two pathways to ongoing research for this rare disease.

  7. The Missing Minority: Understanding The Three Main Barriers To Diversity In Today's Clinical Trials 10/12/2021

    While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations, "unexpected" side effects may be more commonplace while treatment success levels will vary.

  8. Identifying & Understanding Differentiators In CAR T Cell Therapy 8/23/2021

    Hematologist Dr. Robert S. Negrin takes a deep dive into identifying and understanding the central differentiators in cell therapy clinical trials.

  9. It Takes Two – The Importance Of Study Partners In Alzheimer's Disease Clinical Trials 8/23/2021

    Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

  10. What Sets Oncology Clinical Studies Apart From Other Trials? Four Top Differentiators 7/22/2021

    Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.